KVUE Stock Price Today (October 2026) — Kenvue Inc. Analysis & Key Metrics 2026-10-08
Kenvue Inc. (KVUE) is trading at $17.73, up 1.14% today (as of October 2026). The stock continues to show pressure below major moving averages, attracting attention from investors looking for Consumer Defensive growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $19.50 (10.0% upside).
- Volatility is low (14.65% annualized), implying relatively contained price movements for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: steady revenue (3.00% YoY) alongside competitive pressures in the Household & Personal Products space.
KVUE Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Kenvue Inc. - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $41.56B
P/E Ratio
Forward P/E: 15.21
Revenue Growth
Year over Year
Analyst Target
+10.0% upside potential
Key Investor Questions About KVUE
What investors need to know before buying
Based on current market data, KVUE presents a neutral technical setup with mixed signals fundamentals.
- Technicals say: Neutral (RSI 51.35)
- Fundamentals say: Mixed signals (nuanced financial profile)
KVUE's growth trajectory depends on its ability to expand within the Household & Personal Products sector while managing margin pressures.
- Future growth will depend on performance in core Household & Personal Products operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for KVUE investors include debt exposure and competitive dynamics in the Household & Personal Products industry.
- $8.61B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Household & Personal Products.
52-Week Trading Range
Over the past year, KVUE stock traded between $14.02 and $20.13 and currently trades in the middle of that range. Big swings are less likely unless a major catalyst emerges.
Volatility & Risk Profile
With 14.65% annualized volatility and β=0.18, the stock exhibits low sensitivity to market moves—making KVUE suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional ownership with low short interest suggests steadier hands and low immediate risk.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Kenvue Inc's Dividend Analysis
This article first appeared on GuruFocus. Kenvue Inc (NYSE:KVUE) recently announced a total dividend of $0.21 per share, with the ex-dividend date set for 2026-09-21. For income-focused investors, the ex-dividend date is a critical marker: shareholders must own the stock before this date to qualify for the payment.
Kimberly Clark (KMB) Lines Up Assets for $40 Billion Deal Review
Kimberly-Clark (NasdaqGS:KMB) plans to sell assets tied to its planned US$40b acquisition of consumer products group Kenvue. The disposals are aimed at addressing European Union antitrust concerns linked to overlaps in consumer health and personal care brands. Asset sale discussions focus on EU markets where regulators flagged competition issues as part of their ongoing review of the Kenvue deal. Kimberly-Clark's move to sell assets around the US$40b Kenvue deal sits within a broader pattern...
Better Dividend King to Buy and Hold: Johnson & Johnson or Kenvue?
One healthcare dividend payer carries legal risk, the other faces a buyout. Here's which one actually deserves your money.
Should Kenvue’s (KVUE) TYLENOL with Naproxen Launch and Dividend Plan Prompt Investor Reassessment?
Kenvue Inc. previously announced that its Board of Directors declared a quarterly dividend of US$0.21 per share, payable on October 2, 2026, to shareholders of record as of September 21, 2026, while also securing FDA approval for TYLENOL with Naproxen, a first-of-its-kind non-opioid OTC pain reliever backed by multiple clinical studies. By pairing a new, clinically supported TYLENOL with Naproxen launch with ongoing cash returns via dividends, Kenvue is highlighting both product innovation...
Is Kenvue (KVUE) A Bargain Following Its TYLENOL With Naproxen Launch?
Kenvue (KVUE) is on investors’ radar after launching TYLENOL with Naproxen, an FDA-approved, opioid-free over the counter pain reliever that combines acetaminophen and naproxen sodium, backed by extensive clinical research. That launch comes as Kenvue’s share price has softened in the short term, with a 7 day share price return of down 4.43% and a 30 day share price return of down 6.72%. Even though the year to date share price return is 3.41% and the 1 year total shareholder return is 2.85%,...
Kimberly-Clark Moves to Clear EU Hurdle with Kenvue Asset Sales
Kimberly-Clark Corporation (NASDAQ:KMB) is preparing asset sales to address EU antitrust concerns surrounding its planned $40 billion acquisition of Kenvue, according to Reuters. The company is reportedly seeking to offer remedies that could secure European Commission approval by the September 29 deadline, avoiding a more extensive four-month investigation. Similar regulatory concerns have already emerged in […]
Sector Update: Consumer Stocks Mixed Late Afternoon
Consumer stocks were mixed late Monday afternoon, with the State Street Consumer Staples Select Sect
Here's My Pick for the Smartest High-Yield Dividend Stock to Buy Right Now
Kenvue's dependable dividend is above average, and it could go even higher if the company is bought by Kimberly-Clark.
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday Amid AI Pullback
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.6%, and the actively t
Who Buys Colgate’s Cast-Off Brands? Why the Obvious Answers Are Unlikely.
Colgate is reportedly shopping Softsoap, Irish Spring, and Speed Stick with Goldman Sachs running the process, but the names most investors would expect to step up all have reasons to sit this one out.
Explore More Analysis for KVUE
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Nov 2, 2026 (before the open)
Frequently Asked Questions
Common investor questions about Kenvue Inc.
Kenvue Inc. (KVUE) is currently trading at $17.73. The RSI (14-day) is at 51.3, indicating neutral territory. Wall Street analysts have a consensus "hold" recommendation. The mean analyst price target of $19.50 implies 10.0% upside from current levels. Volatility is low at 14.7% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Kenvue Inc. (KVUE): The trailing P/E ratio is 21.07, which is in line with broader market averages. The forward P/E is 15.21, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 1.58, near 1.0, suggesting roughly fair value relative to growth. Price-to-Book is 3.26. Price-to-Sales is 2.23. Valuation should be compared to Household & Personal Products industry peers for context, as different sectors trade at different multiples.
Based on 12 analysts covering KVUE, the consensus price target is $19.50. This represents a 10.0% upside from the current price of $17.73. The range spans from a low target of $18.00 to a high target of $23.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "hold". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Kenvue Inc. (KVUE) pays a dividend with a current yield of approximately 4.74%. The annualized dividend rate is $0.83 per share. The payout ratio is 97.7%, which is relatively high—earnings cover the dividend but there's limited room for increases. The most recent ex-dividend date was Sep 21, 2026.
Key risks for Kenvue Inc. (KVUE) investors include: 1. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 2. Household & Personal Products sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Kenvue Inc.'s (KVUE) current debt and financial health profile: Total debt stands at $8.61B. The debt-to-equity ratio is 0.82x, which is elevated and warrants monitoring, especially in a rising interest rate environment. The current ratio is 1.01, indicating adequate short-term liquidity. The quick ratio is 0.61. The company holds $1.11B in cash and equivalents. Free cash flow is positive at $1.91B, providing a cushion for debt servicing and shareholder returns.